Literature DB >> 20224722

YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.

Craig Horbinski1, Guoji Wang, Clayton A Wiley.   

Abstract

YKL-40 is a secreted chitinase-like molecule whose expression is associated with glioma grade. Expression is higher in astrocytomas than oligodendrogliomas and has been reported to predict shorter survival and radiation resistance in glioblastomas (GBMs). Whether YKL-40 is directly produced by glioma cells or other admixed nonneo-plastic cells, and whether it correlates with 1p/19q status or other hallmark molecular abnormalities, are unclear. A rank-order list of YKL-40 expression was determined immunohistochemically in 79 untreated high-grade adult glio-mas, including 28 anaplastic oligodendrogliomas (AOs) and 51 GBMs. Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations. YKL-40 mRNA in situ hybridization with colocalization assessment via confocal microscopy was also performed. YKL-40 mRNA was abundant in glioma cells as well as reactive astrocytes, but was low in admixed neurons and macrophages. YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001). Among AOs, no difference in YKL-40 expression was seen in tumors with 1p19q codeletion (P = 0.3), but loss of heterozygosity in 10q23 correlated with increased YKL-40 expression (P = 0.03). These data suggest that YKL-40 is predominantly expressed by neoplastic glial cells and is related to certain key molecular alterations.

Entities:  

Keywords:  10q; 1p19q; EGFR; YKL-40; glioblastoma; oligodendroglioma

Mesh:

Substances:

Year:  2010        PMID: 20224722      PMCID: PMC2836500     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  42 in total

1.  Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas.

Authors:  Marc Sanson; Pascal Leuraud; Lucinda Aguirre-Cruz; Jié He; Yannick Marie; Stéphanie Cartalat-Carel; Karima Mokhtari; Hugues Duffau; Jean-Yves Delattre; Khê Hoang-Xuan
Journal:  J Neurosurg       Date:  2002-12       Impact factor: 5.115

2.  High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.

Authors:  Christina Cintin; Julia S Johansen; Ib Jarle Christensen; Paul A Price; Steen Sørensen; Hans Jørgen Nielsen
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

Review 3.  Primary and secondary glioblastomas: from concept to clinical diagnosis.

Authors:  P Kleihues; H Ohgaki
Journal:  Neuro Oncol       Date:  1999-01       Impact factor: 12.300

4.  Expression of p53 and prognosis in children with malignant gliomas.

Authors:  Ian F Pollack; Sydney D Finkelstein; Jeffrey Woods; Judith Burnham; Emiko J Holmes; Ronald L Hamilton; Allan J Yates; James M Boyett; Jonathan L Finlay; Richard Sposto
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

5.  High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.

Authors:  Benny Vittrup Jensen; Julia S Johansen; Paul A Price
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

6.  The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways.

Authors:  Anneliese D Recklies; Chantal White; Hua Ling
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

7.  The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha.

Authors:  Hua Ling; Anneliese D Recklies
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

8.  A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer.

Authors:  Heba Sh Kassem; Vijay Sangar; Richard Cowan; Noel Clarke; Geoffrey P Margison
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

9.  Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.

Authors:  Meena K Tanwar; Mark R Gilbert; Eric C Holland
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

10.  YKL-40, a secreted glycoprotein, promotes tumor angiogenesis.

Authors:  R Shao; K Hamel; L Petersen; Q J Cao; R B Arenas; C Bigelow; B Bentley; W Yan
Journal:  Oncogene       Date:  2009-09-21       Impact factor: 9.867

View more
  17 in total

1.  Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.

Authors:  Camilla Bjørnbak; Christian B Brøchner; Lars A Larsen; Julia S Johansen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2014-03-04       Impact factor: 2.479

2.  Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer.

Authors:  Xiaomei Liu; Yinxu Zhang; Zhitu Zhu; Minwen Ha; Yu Wang
Journal:  Med Oncol       Date:  2014-07-05       Impact factor: 3.064

Review 3.  Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis.

Authors:  Gang Qin; Xianfeng Li; Zilong Chen; Guangcha Liao; Yu Su; Yaode Chen; Wei Zhang
Journal:  Mol Neurobiol       Date:  2016-04-18       Impact factor: 5.590

4.  A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.

Authors:  N K Magdalinou; R W Paterson; J M Schott; N C Fox; C Mummery; K Blennow; K Bhatia; H R Morris; P Giunti; T T Warner; R de Silva; A J Lees; H Zetterberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-01-14       Impact factor: 10.154

5.  Association between human cartilage glycoprotein 39 (YKL-40) and arterial stiffness in essential hypertension.

Authors:  Wei-hong Ma; Xiu-ling Wang; Yi-meng Du; Yi-biao Wang; Yan Zhang; De-e Wei; Lin-lin Guo; Pei-Li Bu
Journal:  BMC Cardiovasc Disord       Date:  2012-05-29       Impact factor: 2.298

Review 6.  Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis.

Authors:  Dan Xie; Ling Feng; Hongyan Huang; Quanzhen Zhao; Pingping Ning; Qiuyan Shen; Haitao Lu; Fang Xu; Yanming Xu
Journal:  Behav Neurol       Date:  2021-05-31       Impact factor: 3.342

7.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

8.  YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

Authors:  Nicolai A Schultz; Julia S Johansen
Journal:  Cancers (Basel)       Date:  2010-07-12       Impact factor: 6.639

Review 9.  Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.

Authors:  Fabio M Iwamoto; Adília Hormigo
Journal:  Front Oncol       Date:  2014-04-28       Impact factor: 6.244

10.  Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma.

Authors:  Xin Zheng; Shan Xing; Xiao-Min Liu; Wen Liu; Dan Liu; Pei-Dong Chi; Hao Chen; Shu-Qin Dai; Qian Zhong; Mu-Sheng Zeng; Wan-Li Liu
Journal:  BMC Cancer       Date:  2014-07-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.